title: An Evaluation of the Efficacy of Selective Alpha-Blockers in the Treatment of Children with Neurogenic Bladder Dysfunction--Preliminary Findings.
abstract: The aim of this study was to assess the usefulness of selective α1-blockers in children with neurogenic urinary tract dysfunctions and increased leak point pressure (LPP). 14 children from age 6 to 16 years with neurogenic urinary tract dysfunctions (neurogenic bladder) and LPP > 40 cm H₂O were enrolled in the study. All patients received a selective α1-blocker (doxazosin) for 6-8 weeks with an initial dosage of 0.03 mg/kg. During the observation period the continuation of oral anticholinergics, Clean Intermittent Catheterization (CIC), observation of "urinary dryness" and urinary incontinence periods were recommended. Patients were scheduled for a follow-up visit and urodynamic investigation after 6-8 weeks after the doxazosin therapy was started. In 4 patients, urine leakage occurred at lower pressures; in 9 patients, no significant changes in urine leak point pressures were detected; in 3 patients, there was a significant increase in the bladder capacity; in one patient, deterioration in continence was noted. The differences both in LPP and LPV before and after the treatment were not statistically significant. Our observations are consistent with the conclusions from other studies and showed no evident efficacy of doxazosin in children with neurogenic bladder.
authors.affiliation: Pediatric Surgery and Urology Department, Neurourology Unit, Poznań University of Medical Sciences, ul. Szpitalna 27/33, Poznań 60-572, Poland. pawelkroll.poczta@gmail.com.
authors.forename: Paweł
authors.initials: P
authors.lastname: Kroll
authors.affiliation: Chair for Rheumatology and Rehabilitation, Poznań University of Medical Sciences, ul. 28 Czerwca 135/147, Poznań 61-545, Poland. ewagajewska1011@gmail.com.
authors.forename: Ewa
authors.initials: E
authors.lastname: Gajewska
authors.affiliation: Pediatric Nephrology Department, Poznań University of Medical Sciences, ul. Szpitalna 27/33, Poznań 60-572, Poland. zachwiej@mp.pl.
authors.forename: Jacek
authors.initials: J
authors.lastname: Zachwieja
authors.affiliation: Chair for Rheumatology and Rehabilitation, Poznań University of Medical Sciences, ul. 28 Czerwca 135/147, Poznań 61-545, Poland. msobieska@ump.edu.pl.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Sobieska
authors.affiliation: Pediatric Surgery and Urology Department, Neurourology Unit, Poznań University of Medical Sciences, ul. Szpitalna 27/33, Poznań 60-572, Poland. mankowskip@wp.pl.
authors.forename: Przemysław
authors.initials: P
authors.lastname: Mańkowski
mesh_terms: D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis* / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000175:diagnosis* / Q000188:drug therapy*; D014563:Urodynamics / Q000502:physiology*
chemical_list: D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin
keywords: alpha-blocker; doxazosin; neurogenic bladder dysfunction; sphincter; urodynamics